Illumina MiSeq i100 Equipment and Maintenance Sole Source

The Illinois Department of Public Health (IDPH) is pursuing a sole source procurement for two Illumina MiSeq i100 Plus Sequencing Systems, with one system designated for the Springfield laboratory and another for the Carbondale laboratory. These advanced benchtop next-generation sequencers are critical for public health functions, including whole-genome sequencing, disease outbreak investigations, respiratory virus surveillance, newborn screening, and clinical assays. Each system includes an integrated touchscreen monitor, on-instrument computer, control software, and hardware-accelerated Dragen Bio-IT secondary analysis pipelines, along with a 12-month Silver Support Plan. The procurement is specifically tailored to meet CDC PulseNet program requirements and includes exclusive FDA-cleared clinical test validations. The solicitation was posted on October 15, 2025, with a response deadline of October 29, 2025, and interested parties must submit any written comments or hearing requests by October 24, 2025, at 4:00 p.m. to the designated information contact.

The contract opportunity appears to be unrestricted, with no specific set-aside designations for disadvantaged enterprises mentioned in the documentation. Illumina, Inc. is the sole source vendor for this procurement, with a unique certification indicating they are the exclusive manufacturer and source for these specific products. The total contract value is $221,408.64, funded through federal funds, with each system and support plan priced at $110,704.32. The procurement covers a contract period from November 1, 2025, to October 31, 2027, and includes initial one-year service plans with options for additional support to ensure continuous operation and maintenance. The systems offer significant operational improvements, including a 50% reduction in per-user operating costs, faster run times, increased sample throughput, and integrated data analysis. Notably, alternative sequencing platforms cannot meet the specific technical, clinical, and programmatic requirements of the IDPH Division of Laboratories, further justifying the sole source approach.